Given its central role in cancer progression, FAK is an attractive target for cancer therapy. Several small molecule inhibitors of FAK have been developed and are currently in various stages of clinical trials. These inhibitors aim to block FAK's kinase activity, thereby disrupting its signaling pathways and reducing tumor growth and metastasis. Some promising results have been observed, particularly when FAK inhibitors are used in combination with other therapies.
